Inclusion Criteria:

   - Written informed consent must be obtained prior to any screening procedures or
   treatment assignment.

   - Has a patient specific batch of CTL019 which is out of specification either due to out
   of specification incoming apheresis or final product not meeting commercial release.

   - Not excluded from commercial manufacturing under the prescribing guidelines for their
   country

   - Out of specification material has not been deemed to pose an undue safety risk to the
   patient

   - Is suffering from a serious or life-threatening disease or condition

   - Repeat leukapheresis is not feasible per the treating physician assessment

   - Does not have access to a comparable or satisfactory alternative treatment

   - Is not eligible for participation in any of the IMP's ongoing clinical trials or has
   recently completed a clinical trial that has been terminated and, after considering
   other options, the clinical team has determined that treatment is necessary and there
   are no other feasible alternatives for the patient

   - Meets any other relevant medical criteria for compassionate use of the investigational
   product

   - Is not being transferred from an ongoing clinical trial for which they are still
   eligible

Exclusion Criteria:

   - Product can be commercially manufactured per the specification of the country in which
   treatment will occur.

   - Patients who are able to repeat leukapheresis.

   - Evidence of CD19 negative disease

   - HIV positive patients

   - Patients with active replication of Hep B or active or latent Hep C

   - History of hypersensitivity to any drugs or metabolites of similar chemical classes as
   tisagenlecleucel.

   - Uncontrolled active infection or inflammation

   - History of unstable angina or MI within 6 months prior to screening

   - Any medical condition identified by the investigator that may impact the assessment of
   the safety or efficacy outcomes in relation to study treatment